See today's BioWorld
To read the full story, subscribe or sign in.

Aardvark stock sinks first day; IPO to fund obesity drugs

Feb. 13, 2025
By Karen Carey
Raising $94.2 million in gross proceeds, Aardvark Therapeutics Inc. became the fifth biopharma company to list on Nasdaq so far in 2025.
BioWorld Financings Endocrine/metabolic Obesity IPO